PubMed Health⌕ Search

Biomedical subjects

B M Korsantiia

Publications and source records attributed to B M Korsantiia.

14 recordsLinked to original sources
PubMed1988

[Indices of the interferon system in patients with viral myocarditis and dilated cardiomyopathy].

The authors presented some data on the investigation of the interferon system in patients with dilatation cardiomyopathy (DCM) and viral myocarditis (VM). Diagnosis was verified according to the WHO criteria. Altogether 10 DCM patients and 24 VM patients with a grave course were investigated. Antibodies to Coxsackie B virus and influenza were detected in the VM patients. A decrease in the alpha- and gamma-interferon activity was shown in all DCM patients. The VM patients with a grave course also demonstrated a decrease in the alpha- and especially gamma-interferon (immune) activity. Methods of immune correction in such patients were discussed.

Antibodies, Viral↗
PubMedDate not supplied

[Mechanisms of action of LB-plaferon and fenovin in the cases of Rausche virus leukemia].

The aim of our investigation was to examine the mechanisms of protective features of plaferon LB and fenovit in mice infected with Rausche virus. It was found that in erythroblasts from peripheral blood and spleen, which appeared 12-14 days after infection, the highest percent of determined virus antigens was approximately 47% (range 35,5 to 58,4) which was followed by decrease of the concentration of virus antigens (between 5-12%) in following days and increase of uninfected cells as a result of division of non-contaminated erythroblasts. Mechanism of action of plaferon LB and fenovit was manifested in the reconstitution of mechanisms of apoptosis among erythroblasts, which did not contain synthesized Rausche virus. Impairment of functional activity and antivirus resistance of macrophagal phagocytes are playing an important role not only in the pathogenesis of murine viral leukemia caused by Rausche virus, but also during human leukemia. Correction of functional status of above -- mentioned diseases using plaferon LB and fenovit is presenting as a new and prospective way.

Animals↗
PubMedDate not supplied

[Physicochemical and biological properties of human placental amniotic interferon].

The possibility of generating large quantities of highly active interferon from human placenta amniotic membrane (plaferon) has been demonstrated. Plaferon is innocuous and nonreactogenic in experimental models and has an antiviral effect of wide spectrum. The activity is resistant to DNase, RNase, lipase, and stable at pH 2. A polyclonal serum to human leukocyte interferon and monoclonal NK-2 antibody did not inhibit the antiviral activity of plaferon. The level of hormones in plaferon and leukocyte interferon preparations was practically similar. In diploid cultures of human fibroblasts the antiviral condition under the effect of plaferon developed slower than under the effect of leukocyte interferon.

Amnion↗